Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Antiviral Res. 2011 Apr 23;90(3):227–230. doi: 10.1016/j.antiviral.2011.04.006

Figure 2.

Figure 2

HBsAg-specific IgG response to no treatment (NT), vehicle, JVRS-100 (IV, 10 μg), HBsAg (i.m., 5 μg), or HBsAg and JVRS-100 (i.m., 5 μg, 10 were treated A) once every 3 weeks on days 1, 22, and 43 and necropsied on day 57, and B) once every 2 weeks on days 1, 14, 28, 42, 56 and necropsied on day 70. Plasma was assayed for HBsAg-specific IgG. Ten animals were included in each group. (***P ≤ 0.001 using one-way analysis of variance.)